KR20220010478A - 기도 감염의 치료 또는 예방용 서브유닛 백신 - Google Patents

기도 감염의 치료 또는 예방용 서브유닛 백신 Download PDF

Info

Publication number
KR20220010478A
KR20220010478A KR1020217034461A KR20217034461A KR20220010478A KR 20220010478 A KR20220010478 A KR 20220010478A KR 1020217034461 A KR1020217034461 A KR 1020217034461A KR 20217034461 A KR20217034461 A KR 20217034461A KR 20220010478 A KR20220010478 A KR 20220010478A
Authority
KR
South Korea
Prior art keywords
protein
val
leu
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217034461A
Other languages
English (en)
Korean (ko)
Inventor
파비앙 페루지
클라우스 슈밤본
볼프강 슈욀러
울반 룬트베르크
안드레아스 마인케
Original Assignee
발네바 에스이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발네바 에스이 filed Critical 발네바 에스이
Publication of KR20220010478A publication Critical patent/KR20220010478A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217034461A 2019-05-20 2020-05-19 기도 감염의 치료 또는 예방용 서브유닛 백신 Ceased KR20220010478A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
EP19175413.4 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (1)

Publication Number Publication Date
KR20220010478A true KR20220010478A (ko) 2022-01-25

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034461A Ceased KR20220010478A (ko) 2019-05-20 2020-05-19 기도 감염의 치료 또는 예방용 서브유닛 백신

Country Status (21)

Country Link
US (3) US12162907B2 (https=)
EP (1) EP3972639A1 (https=)
JP (1) JP2022533318A (https=)
KR (1) KR20220010478A (https=)
CN (1) CN114127101A (https=)
AU (1) AU2020277661A1 (https=)
BR (1) BR112021021637A2 (https=)
CA (1) CA3138064A1 (https=)
CL (1) CL2021002819A1 (https=)
CO (1) CO2021014694A2 (https=)
EC (1) ECSP21079178A (https=)
GB (1) GB2598494B (https=)
IL (1) IL287099A (https=)
MX (1) MX2021013111A (https=)
MY (1) MY208001A (https=)
PE (1) PE20220400A1 (https=)
PH (1) PH12021552736A1 (https=)
SA (1) SA521430813B1 (https=)
SG (1) SG11202110646PA (https=)
WO (1) WO2020234300A1 (https=)
ZA (1) ZA202106883B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
KR102860080B1 (ko) 2020-10-09 2025-09-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 융합전-안정화된 hmpv f 단백질
AU2021380755A1 (en) 2020-11-13 2023-06-22 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体：制造方法和用途
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119176858B (zh) * 2024-11-22 2026-01-09 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
WO2016103238A1 (en) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
CA2996762A1 (en) * 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신

Also Published As

Publication number Publication date
WO2020234300A1 (en) 2020-11-26
PH12021552736A1 (en) 2022-07-11
MX2021013111A (es) 2021-11-17
MY208001A (en) 2025-04-03
CO2021014694A2 (es) 2022-01-17
US12162909B2 (en) 2024-12-10
SG11202110646PA (en) 2021-10-28
IL287099A (en) 2021-12-01
GB2598494B (en) 2024-07-24
JP2022533318A (ja) 2022-07-22
SA521430813B1 (ar) 2024-04-27
ECSP21079178A (es) 2021-11-30
BR112021021637A2 (pt) 2021-12-21
GB202114836D0 (en) 2021-12-01
CN114127101A (zh) 2022-03-01
ZA202106883B (en) 2022-07-27
EP3972639A1 (en) 2022-03-30
US20250171501A1 (en) 2025-05-29
CL2021002819A1 (es) 2022-07-08
AU2020277661A1 (en) 2021-10-21
PE20220400A1 (es) 2022-03-22
US20220185847A1 (en) 2022-06-16
GB2598494A (en) 2022-03-02
US20240067681A1 (en) 2024-02-29
US12162907B2 (en) 2024-12-10
CA3138064A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US12162909B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
US11786591B2 (en) Recombinant metapneumovirus F proteins and their use
US9060975B2 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
KR102252163B1 (ko) 인플루엔자 바이러스 백신 및 그의 용도
JP2023524054A (ja) ベータコロナウイルスの予防と治療
JP2018520159A (ja) Ｒｓｖに対するワクチン
KR20230167017A (ko) 인간 메타뉴모 바이러스 백신
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
CN117202928A (zh) 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗
KR20230084478A (ko) 면역원성 코로나 바이러스 융합 단백질 및 관련 방법
AU2022368453A1 (en) Chimeric betacoronavirus spike polypeptides
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
CN119161495B (zh) 呼吸道合胞病毒重构多肽及其应用
HK40098178A (zh) 人偏肺病毒疫苗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601